2023
Michael, B. D., Dunai, C., Needham, E. J., Tharmaratnam, K., Williams, R., Huang, Y., . . . Menon, D. K. (2023). Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses.. Nature communications, 14(1), 8487. doi:10.1038/s41467-023-42320-4DOI: 10.1038/s41467-023-42320-4
Alrezaihi, A., Penrice-Randal, R., Dong, X., Prince, T., Randle, N., Semple, M. G., . . . Hiscox, J. A. (2023). Enrichment of SARS-CoV-2 sequence from nasopharyngeal swabs whilst identifying the nasal microbiome. Journal of Clinical Virology, 105620. doi:10.1016/j.jcv.2023.105620DOI: 10.1016/j.jcv.2023.105620
Alruwaili, M., Armstrong, S., Prince, T., Erdmann, M., Matthews, D. A., Luu, L., . . . Hiscox, J. A. (2023). SARS-CoV-2 NSP12 associates with TRiC and the P323L substitution acts as a host adaption.. Journal of virology, 97(11), e0042423. doi:10.1128/jvi.00424-23DOI: 10.1128/jvi.00424-23
Collings, K., Boisdon, C., Sham, T. -T., Skinley, K., Oh, H. -K., Prince, T., . . . Maher, S. (n.d.). Attaching protein-adsorbing silica particles to the surface of cotton substrates for bioaerosol capture including SARS-CoV-2. Nature Communications, 14(1). doi:10.1038/s41467-023-40696-xDOI: 10.1038/s41467-023-40696-x
Goldswain, H., Dong, X., Penrice-Randal, R., Alruwaili, M., Shawli, G. T., Prince, T., . . . Hiscox, J. A. (2023). The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.. Genome biology, 24(1), 47. doi:10.1186/s13059-023-02881-5DOI: 10.1186/s13059-023-02881-5
Liew, F., Talwar, S., Cross, A., Willett, B. J., Scott, S., Logan, N., . . . Openshaw, P. J. M. (2023). SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBIOMEDICINE, 87. doi:10.1016/j.ebiom.2022.104402DOI: 10.1016/j.ebiom.2022.104402
2022
Poh, X. Y., Tan, C. W., Lee, I. R., Chavatte, J. -M., Fong, S. -W., Prince, T., . . . Young, B. E. (n.d.). Antibody response of heterologous vs homologous mRNA vaccine boosters against the SARS-CoV-2 Omicron variant: interim results from the PRIBIVAC study, A Randomized Clinical Trial. Clinical Infectious Diseases. doi:10.1093/cid/ciac345DOI: 10.1093/cid/ciac345
Vink, E., Davis, C., MacLean, A., Pascall, D., McDonald, S. E., Gunson, R., . . . Ho, A. (2022). Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study. OPEN FORUM INFECTIOUS DISEASES, 9(11). doi:10.1093/ofid/ofac531DOI: 10.1093/ofid/ofac531
Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages (Journal article)
Prince, T., Dong, X., Penrice-Randal, R., Randle, N., Hartley, C., Goldswain, H., . . . Hiscox, J. A. (2022). Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. MSPHERE, 7(3). doi:10.1128/msphere.00913-21DOI: 10.1128/msphere.00913-21
Dong, X., Penrice-Randal, R., Goldswain, H., Prince, T., Randle, N., Donovan-Banfield, I., . . . Hiscox, J. A. (2022). Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers. GIGASCIENCE, 11. doi:10.1093/gigascience/giac045DOI: 10.1093/gigascience/giac045
Narhi, F., Moonesinghe, S. R., Shenkin, S. D., Drake, T. M., Mulholland, R. H., Donegan, C., . . . Docherty, A. B. (2022). Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study. LANCET DIGITAL HEALTH, 4(4). Retrieved from https://www.webofscience.com/
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., . . . Screaton, G. R. (2022). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.. Cell, 185(3), 467-484.e15. doi:10.1016/j.cell.2021.12.046DOI: 10.1016/j.cell.2021.12.046
Anderson, E. R., Prince, T., Turtle, L., Hughes, G. L., & Patterson, E. I. (2022). Methods of SARS-CoV-2 Inactivation.. Methods in molecular biology (Clifton, N.J.), 2452, 465-473. doi:10.1007/978-1-0716-2111-0_25DOI: 10.1007/978-1-0716-2111-0_25
Knight, S. R., Gupta, R. K., Ho, A., Pius, R., Buchan, I., Carson, G., . . . Harrison, E. M. (2022). Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. THORAX, 77(6), 606-615. doi:10.1136/thoraxjnl-2021-217629DOI: 10.1136/thoraxjnl-2021-217629
2021
Niemi, M. E. K., Karjalainen, J., Daly, M., Ganna, A., Mehtonen, J., Cordioli, M., . . . Dopazo, X. (2021). Mapping the human genetic architecture of COVID-19. NATURE, 600(7889), 472-+. doi:10.1038/s41586-021-03767-xDOI: 10.1038/s41586-021-03767-x
Antiviral activity of Molnupiravir precursor NHC against SARS-CoV-2 Variants of Concern (VOCs) and implications for the therapeutic window and resistance (Preprint)
DOI: 10.1101/2021.11.23.469695
de, S. T. I., Liu, G., Lindsey, B. B., Dong, D., Moore, S. C., Hsu, N. S., . . . Dong, T. (2021). The impact of viral mutations on recognition by SARS-CoV-2 specific T cells. ISCIENCE, 24(11). doi:10.1016/j.isci.2021.103353DOI: 10.1016/j.isci.2021.103353
Wickenhagen, A., Sugrue, E., Lytras, S., Kuchi, S., Noerenberg, M., Turnbull, M. L., . . . Wilson, S. J. (2021). A prenylated dsRNA sensor protects against severe COVID-19. SCIENCE, 374(6567). doi:10.1126/science.abj3624DOI: 10.1126/science.abj3624
Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., . . . Wang, C. -I. (2021). Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. NPJ VACCINES, 6(1). doi:10.1038/s41541-021-00389-2DOI: 10.1038/s41541-021-00389-2
Huo, J., Mikolajek, H., Le Bas, A., Clark, J. J., Sharma, P., Kipar, A., . . . Moynie, L. (2021). A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-25480-zDOI: 10.1038/s41467-021-25480-z
Smith, S. L., Anderson, E. R., Cansado-Utrilla, C., Prince, T., Farrell, S., Brant, B., . . . Patterson, E. I. (2021). SARS-CoV-2 neutralising antibodies in dogs and cats in the United Kingdom.. Current research in virological science, 2, 100011. doi:10.1016/j.crviro.2021.100011DOI: 10.1016/j.crviro.2021.100011
Russell, C. D., Fairfield, C. J., Drake, T. M., Turtle, L., Seaton, R. A., Wootton, D. G., . . . Ho, A. (2021). Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. LANCET MICROBE, 2(8), E354-E365. doi:10.1016/S2666-5247(21)00090-2DOI: 10.1016/S2666-5247(21)00090-2
Drake, T. M., Riad, A. M., Fairfield, C. J., Egan, C., Knight, S. R., Pius, R., . . . Semple, M. G. (2021). Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study. LANCET, 398(10296), 223-237. Retrieved from https://www.webofscience.com/
Docherty, A., Mulholland, R., Lone, N. I., Cheyne, C., De Angelis, D., Diaz-Ordaz, K., . . . Semple, M. (2021). Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 773-785. doi:10.1016/S2213-2600(21)00175-2DOI: 10.1016/S2213-2600(21)00175-2
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study. (Journal article)
Drake, T. M., Fairfield, C. J., Pius, R., Knight, S. R., Norman, L., Girvan, M., . . . ISARIC4C Investigators. (2021). Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.. The Lancet. Rheumatology, 3(7), e498-e506. doi:10.1016/s2665-9913(21)00104-1DOI: 10.1016/s2665-9913(21)00104-1
Yates, T., Zaccardi, F., Islam, N., Razieh, C., Gillies, C. L., Lawson, C. A., . . . Khunti, K. (2021). Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID-19: Analysis of the ISARIC CCP-UK Cohort. OBESITY, 29(7), 1223-1230. doi:10.1002/oby.23178DOI: 10.1002/oby.23178
Bloom, C. I., Drake, T. M., Docherty, A. B., Lipworth, B. J., Johnston, S. L., Nguyen-Van-Tam, J. S., . . . Openshaw, P. J. M. (2021). Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19 a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. LANCET RESPIRATORY MEDICINE, 9(7), 699-711. doi:10.1016/S2213-2600(21)00013-8DOI: 10.1016/S2213-2600(21)00013-8
Leclerc, Q. J., Fuller, N. M., Keogh, R. H., Diaz-Ordaz, K., Sekula, R., Semple, M. G., . . . Knight, G. M. (2021). Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England. BMC HEALTH SERVICES RESEARCH, 21(1). doi:10.1186/s12913-021-06509-xDOI: 10.1186/s12913-021-06509-x
Gupta, R. K., Harrison, E. M., Ho, A., Docherty, A. B., Knight, S. R., van Smeden, M., . . . Noursadeghi, M. (2021). Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. LANCET RESPIRATORY MEDICINE, 9(4), 349-359. doi:10.1016/S2213-2600(20)30559-2DOI: 10.1016/S2213-2600(20)30559-2
Prince, T., Smith, S. L., Radford, A. D., Solomon, T., Hughes, G. L., & Patterson, E. I. (n.d.). SARS-CoV-2 Infections in Animals: Reservoirs for Reverse Zoonosis and Models for Study. Viruses, 13(3), 494. doi:10.3390/v13030494DOI: 10.3390/v13030494
Dong, X., Penrice-Randal, R., Goldswain, H., Prince, T., Randle, N., Salguero, J., . . . COVID-19 Genomics UK (COG-UK) Consortium. (2021). Identification and quantification of SARS-CoV-2 leader subgenomic mRNA gene junctions in nasopharyngeal samples shows phasic transcription in animal models of COVID-19 and dysregulation at later time points that can also be identified in humans. doi:10.1101/2021.03.03.433753DOI: 10.1101/2021.03.03.433753
2020
Patterson, E. I., Elia, G., Grassi, A., Giordano, A., Desario, C., Medardo, M., . . . Decaro, N. (2020). Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. NATURE COMMUNICATIONS, 11(1). doi:10.1038/s41467-020-20097-0DOI: 10.1038/s41467-020-20097-0
Thompson, C. P., Grayson, N. E., Paton, R. S., Bolton, J. S., Lourenco, J., Penman, B. S., . . . Simmonds, P. (2020). Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020. EUROSURVEILLANCE, 25(42), 33-41. doi:10.2807/1560-7917.ES.2020.25.42.2000685DOI: 10.2807/1560-7917.ES.2020.25.42.2000685
Clark, J., Penrice-Randal, R., Sharma, P., Kipar, A., Dong, X., Pennington, S., . . . Stewart, J. (2020). Sequential infection with influenza A virus followed by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) leads to more severe disease and encephalitis in a mouse model of COVID-19. doi:10.1101/2020.10.13.334532DOI: 10.1101/2020.10.13.334532
Drake, T. M., Docherty, A. B., Harrison, E. M., Quint, J. K., Adamali, H., Agnew, S., . . . ISARIC4C Investigators. (2020). Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease: An International Multicenter Study.. Am J Respir Crit Care Med. doi:10.1164/rccm.202007-2794OCDOI: 10.1164/rccm.202007-2794OC
Patterson, E. I., Prince, T., Anderson, E. R., Casas-Sanchez, A., Smith, S. L., Cansado-Utrilla, C., . . . Hughes, G. L. (2020). Methods of inactivation of SARS-CoV-2 for downstream biological assays.. The Journal of infectious diseases. doi:10.1093/infdis/jiaa507DOI: 10.1093/infdis/jiaa507
Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel [version 1; peer review: 2 approved] (Journal article)
Adams, E. R., Ainsworth, M., Anand, R., Andersson, M. I., Auckland, K., Baillie, J. K., . . . Whitehouse, J. (2020). Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel [version 1; peer review: 2 approved]. Wellcome Open Research, 5. doi:10.12688/wellcomeopenres.15927.1DOI: 10.12688/wellcomeopenres.15927.1
National COVID Testing Scientific Advisory Panel., Adams, E., Ainsworth, M., Anand, R., Andersson, M., Auckland, K., . . . Whitehouse, J. (2020). Antibody testing for COVID-19: A report from the National COVID Scientific Advisory Panel. doi:10.1101/2020.04.15.20066407DOI: 10.1101/2020.04.15.20066407
2019
141 Systematic cerebrospinal fluid testing improves pathogen detection among childhood central nervous system infections in Yogyakarta, Indonesia (Conference Paper)
Griffiths, M. J., Aifa, B., Prince, T., & Solomon, T. (2019, January 23). 141 Systematic cerebrospinal fluid testing improves pathogen detection among childhood central nervous system infections in Yogyakarta, Indonesia. In Developmental Medicine and Child Neurology Vol. 61 (pp. 15-112). LIverpool: Wiley-Blackwell.
Oral Session 3 Thursday 24th January 2019 - Improving the diagnosis of neurosurgical CSF infections (Conference Paper)
Griffiths, M. J., Van Tonder, L., Prince, T., Solomon, T., & Mallucci, C. (2019, January 23). Oral Session 3 Thursday 24th January 2019 - Improving the diagnosis of neurosurgical CSF infections. In Developmental Medicine and Child Neurology Vol. 61 (pp. 4-15). Liverpool: Wiley-Blackwell.
2018
The role of SIGLEC-1 in flavivirus infections (Conference Paper)
Prince, T. A. C., Medialdea Carrera, R., Rainbow, L., Solomon, T., Blake, N., & Griffiths, M. J. (2018). The role of SIGLEC-1 in flavivirus infections. In Encephalitis Society Conference. London.
2013
Evaluation of the utility of probiotics for the prevention of Infections in a model of the skin. (Thesis / Dissertation)
Prince, T. A. C. (2013). Evaluation of the utility of probiotics for the prevention of Infections in a model of the skin..
2012
Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion. (Journal article)
Prince, T., McBain, A. J., & O'Neill, C. A. (2012). Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion.. Applied and environmental microbiology, 78(15), 5119-5126. doi:10.1128/aem.00595-12DOI: 10.1128/aem.00595-12
